A Double-Blinded, Randomized, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Antiviral Activity of TD-6450, a NS5A Inhibitor, in Treatment Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)
Phase of Trial: Phase I
Latest Information Update: 17 Sep 2018
Price : $35 *
At a glance
- Drugs TF 6450 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Proof of concept
- Sponsors Theravance
- 01 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Nov 2014 Interim results published in a Theravance Biopharma media release.
- 22 May 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.